Kornimate/medical-research-clean huggingface dataset:
role of melatonin supplementation in follicular fluid of in vitro fertilization (ivf) patients with polycystic ovarian syndrome

Conditions: Polycystic Ovary Syndrome

Summary: to evaluate the effects of melatonin supplementation on the main in vitro fertilization (ivf) outcomes during ovarian stimulation in patients with polycystic ovarian syndrome (pcos).

polycystic ovarian syndrome (pcos) is a common endocrine disorder that causes infertility due to anovulation in women of reproductive age. anovulation and also decreased oocyte and embryo quality may be cause of infertility in women with pcos. furthermore, the reactive oxygen species (ros) induce oxidative stress which may be responsible for poor oocyte quality. the ros generation from mononuclear cells is elevated in women with pcos and a significant increment of lipid peroxidation products in women with pcos has been reported. melatonin is a documented powerful free radical scavenger and a broad spectrum antioxidant. it has been observed that a non-pcos group co-treated with inositol, folic acid, and melatonin (inofolic plus by lo.li.pharma) results in a significantly greater mean number of mature oocytes, and a lower mean number of immature oocytes in patients with low oocyte quality history when compared to treatment only with inositol and folic acid (inofolic by lo.li.pharma). the aim of the study is to evaluate the possible effects of melatonin supplementation on the main ivf outcomes during ovarian stimulation of patients with pcos. from july 2009 to december 2011, 358 patients with pcos (rotterdam criteria) were enrolled in this prospective randomized controlled trial.

Eligibility criteria:
inclusion criteria: * diagnosis of pcos * irregular menstrual cycle (\> than 28-30 days) * normal uterine cavity * body mass index of 20 to 26 kg/m2 * first ivf treatment exclusion criteria: * presence of tubal, uterine, genetics and male causes of infertility * diagnosis of cancer * hormonal treatment in the last six months

Keywords: intrafollicular melatonin pcos embryos quality oocytes quality
covid 19 seroprevalence amongst healthcare workers in jhah

Conditions: COVID 19

Summary: healthcare workers play a critical role in fighting the pandemic, not only by managing the patients' health clinically, but also by implementing adequate measures for infection prevention and control in healthcare facilities. this puts healthcare workers at a greater risk of acquiring the disease. covid-19 is caused by severe acute respiratory syndrome coronavirus -2 (sars-cov-2) and many people can be infected with it asymptomatically and undetectably. serology is an antibody test that provides additional information to polymerase chain-reaction (pcr) testing as it is the only way to reliably establish the fraction of the population that was infected . seroconversion is the development of antibodies in the blood which can confirm suspected cases after the fact and reveal who was infected but asymptomatic and never realized it. antibodies are specific proteins created as the body's response to the infection and this test is essential for detecting infected individuals with few or no symptoms at all.


Eligibility criteria:
inclusion criteria: 1. adult. 2. jhah employee 3. housekeepers (this group of staff are outsourced at jhah) exclusion criteria: 1. any participant exhibiting covid 19 symptoms

Keywords: covid 19 coronavirus sars-cov-2
comparison of contrast enhanced mammography to breast mri in screening patients at increased risk for breast cancer

Conditions: Women at Increased Risk for Developing Breast Carcinoma

Summary: the purpose of this study is to determine if contrast enhanced spectral mammography (cesm) will be able to detect smaller/earlier breast cancers as well as breast mri can.


Eligibility criteria:
inclusion criteria: * women considered at increased risk for developing breast carcinoma (those with a lifetime risk of \>15%due to family history, genetic predisposition, prior radiation therapy to the chest, prior biopsy showing a high risk lesion, or personal history of breast cancer) that are being screened with breast mri. * women who have a screening digital mammogram on the day of cesm or within 365 days prior exclusion criteria: * women under 21. * pregnant or possibly pregnant. * women who have a contraindication to the intravenous use of iodinated - contrast agent (i.e., allergy to iodinated contrastor severely impaired renal function with a creatinine level \> or = to 1.3). * women with breast implants. * women with pacemakers. * women with aneurysm clips that don't allow for mri. * women too claustrophobic to undergo mri.

Keywords: mammography (cesm) mri breast screening 12-214
cost-effectiveness of and long-term outcomes following acupuncture treatment for osteoarthritis of the knee

Conditions: Osteoarthritis, Knee

Summary: the purpose of this study is to estimate the cost-effectiveness of acupuncture and to determine the long-term outcomes and health care utilization of people with osteoarthritis (oa) of the knee.

osteoarthritis (oa) makes up a large proportion of the disability and economic costs in the u.s. the knee is the most common site of oa and is a common cause of disability and the leading indication of total knee replacement in the elderly. there are presently no curative therapies for oa. recently, increased attention has focused on the use of complementary and alternative medicine (cam) therapies, such as acupuncture, especially for patients who have failed to respond to more standard therapy. little is known of the long-term health services utilization and outcomes of patients with knee oa. this study will evaluate the cost effectiveness and overall outcomes of acupuncture for oa treatment. participants in this study will be randomly assigned to receive either acupuncture or placebo. surveys and questionnaires will be used to assess participants. data will be collected on the short- and long-term utilization of health services as well as on pain and physical function.

Eligibility criteria:
inclusion criteria: * diagnosis of osteoarthritis (oa)
risperidone for treatment of cocaine dependence in outpatients - 12

Conditions: Cocaine-Related Disorders

Summary: the purpose of this study is to evaluate pharmacological efficacy and clinical safety of risperidone in the treatment of cocaine and amphetamine dependence.


Eligibility criteria:
inclusion criteria: m/f ages 21-50 . meet dsm-iv criteria for cocaine dependence. agree to conditions of the study and sign informed consent. exclusion criteria: psychiatric disorder that requires medication therapy. history of seizures. pregnant and/or nuring women. dependence on etoh or benzodiazepines or other sedative/hypnotics. acute hepatitis. other medical condtions that deem participation to be unsafe.

Keywords: cocaine dependence
an electrocardiogram study to evaluate the effect of vanzacaftor on the qt/qtc interval in healthy participants

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the effect of vanzacaftor (vnz) on qtcf, as well as the pharmacokinetic (pk), safety, and tolerability of vnz in healthy participants.

this clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (that is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(a) of the public health service act and 42 cfr 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the public health service act or 42 cfr 11.24 and 11.44.).

Eligibility criteria:
key inclusion criteria: * body mass index (bmi) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), both inclusive * male and female participants of age 18 to 45 years, both inclusive * serum potassium, calcium, and magnesium values within normal ranges key exclusion criteria: * median qtcf\>450 msec on triplicate 12-lead ecgs * history of conduction abnormalities other protocol defined inclusion/exclusion criteria may apply.
an open-label feasibility/pilot study with [123i]-ibzm spect (dopa-syn)

Conditions: Parkinson's Disease

Summary: this study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. this research study uses \[123i\]-ibzm and dynamic spect imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

this is a pilot evaluation of dopaminergic function in pd using a bolus plus constant infusion protocol with \[123i\]-ibzm and spect to evaluate the potential for carbidopa/l-dopa alone or carbidopa/l-dopa/entacapone to produce displacement of striatal radioactivity for assessment of intrasynaptic dopamine. we will assess the feasibility of this paradigm for detecting l-dopa effects on the spect signal in subjects with pd with disease duration of greater than 4yrs and with a stable response to l-dopa. each subject will undergo three \[123i\]-ibzm studies separated by 1-2 weeks. subjects will be off medication for at least 12 h prior to study for each of the three scan days patients will receive a constant intravenous infusion of \[123i\]-ibzm over 4-5 hours to establish an equilibrium binding condition of the radiotracer at striatal d2/d3 receptors. three baseline spect acquisitions will be obtained prior to medication dosing to establish a stable baseline. at approximately 5 h after the initiation of the infusion subjects will receive a single oral dose of either carbidopa/levodopa (37.5mg/150mg or 50mg/250mg), or carbidopa/levodopa/entacapone (either 37.5mg/150mg/200mg- stalevo or 50/250mg/200mg).

Eligibility criteria:
main inclusion criteria: * the patient is aged 30 years or older. * written informed consent is obtained. * patients have a diagnosis of idiopathic parkinson's disease. * hoehn and yahr stages for patients are i-iii. * patients have a diagnosis\> 4 yrs prior to screening * patients are treated with carbidopa/levodopa with \> 300 mg levodopa. main exclusion criteria: * the patient has atypical or drug-induced parkinson's disease. * the patient has dementia (mmse 24). * the patient has a clinically significant clinical laboratory values, and/or medical or psychiatric illness. * the patient has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery). * the patient has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease. * the patient has been treated with a dopamine agonist within the past 30 days. * concomitant treatment with monoamine oxidase (mao)-inhibitors (except selegiline \<10 mg/day) within 30 days prior to the screening visit * patient has a history of iodine allergy

Keywords: parkinson brain imaging
pelvic floor muscle training on the quality of life in women with urinary incontinence

Conditions: Urinary Incontinence; Quality of Life

Summary: aim: to assess the influence of pelvic floor muscles group training in the quality of life and functionality of these muscles in women with ui. study design: this is a randomized controlled trial.

search location: urogynecology ambulatory care of porto alegre clinical hospital (hcpa) patients or participants: women will be included in aged 35-70 years who have had sexual intercourse in the last 12 months and who are able to understand the instruments, besides signing an informed consent form. women will be excluded with latex allergy, who have made pelvic radiotherapy, or be undergoing chemotherapy, puerperal a year, or who use antidepressants and / or anxiolytics. intervention and measures: the evaluation consists of a medical history form, which will include personal data; the assessment of the map function is performed by the pressure biofeedback; for assessment of quality of life will use the questionnaire icqi-sf and sexual function the pisq-12 before and after pelvic floor muscle training. expected results: to estimate effectiveness of pelvic floor muscle training in the quality of life and functionality of these muscles in women with urinary incontinence.

Eligibility criteria:
inclusion criteria: * female; * have urinary incontinence; * age between 35 and 70 years; * have sexual intercourse in the last 6 months; * participants should understand the instruments used in the research; * accept to participate in the study and sign the term of free and informed consent. exclusion criteria: * latex allergy; * have performed or are undergoing pelvic radiotherapy; * be performing chemotherapy treatment; * women who delivered during the last 12 months; * have participated in individual or group map training in the last 6 months; * have contraction of the pelvic floor muscles grade zero (0).

Keywords: women pelvic floor muscles
lifestyle modification program for patients with chronic pain conditions

Conditions: Chronic Pain

Summary: in this observational study the effects of a lifestyle modification program - offered as a semi-residential day care clinic - on pain, disability, quality of life and satisfaction with life will be investigated. furthermore the influence of mindfulness, acceptance and coping, and acquired changes in lifestyle behaviors on the outcome after the program will be evaluated. effects will be measured after completion of the program (3 months), and at 6 and 12 months follow up after start of the program, i.e. each outcome measure will be taken 4 times within 12 months.

see above

Eligibility criteria:
inclusion criteria: * 18-78 * diagnosed with any chronic pain condition * physical and mental ability to participate in the program and the study * written informed consent exclusion criteria: * participation in any other clinical study focusing on psychological or behavioral intervention
dynamic measurement of renal functional reserve as a predictor of long-term renal function

Conditions: Adult Polycystic Kidney Disease; Kidney Neoplasms; Kidney Dysfunction

Summary: the number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally. an accurate measurement of kidney function is urgently needed to better understand and treat loss of renal function. kidneys have an intrinsic reserve capacity to respond to a higher work load by increasing filtration in their nephrons. the number of nephrons and their reserve capacity define how well kidneys can adapt to an increased demand and disease. the degree of renal reserve capacity becomes particularly important when the number of functioning nephrons is significantly reduced either due to surgical removal of one kidney as in living kidney donation or in tumor nephrectomy or due to progressive injury as in autosomal dominant polycystic kidney disease (adpkd). a reduced functional reserve likely reflects an impaired adaptive capacity and increased risk of accelerated loss of function in the remaining single kidney or in kidneys exposed to a disease. despite the importance of accurately measuring baseline and reserve capacity renal function, due to the time- and laborintensive procedure, in clinical routine this testing is rarely done. investigators aim to measure renal functional reserve (rfr) and loss of function in patients undergoing nephrectomy (living kidney donors and renal tumor patients) as well as in patients with adpkd. the results should provide evidence whether renal functional reserve indeed predicts adaptive capacity and functional loss after removal of a healthy kidney (living donors), of a tumor kidney (cancer patients) or in progressive kidney disorders (adpkd patients). investigators are confident that the proposed project will enhance the understanding of progressive kidney disease and with this improve donor safety, planning of tumor nephrectomy, and prediction of renal functional loss as well as provide a strong argument that dynamic renal function testing, i.e. accurate measurement of baseline and reserve capacity, is necessary in certain disease entities.

the measurement of rfr will be performed by dynamic testing of the changes in baseline glomerular filtration rate (gfr) induced by an oral protein load. sinistrin (a polyfructosan with identical clearance characteristics to inulin) will be used to measure gfr.

Eligibility criteria:
inclusion criteria: * potential living kidney donor * patients with diagnosed adpkd * patients with primary kidney tumor requiring nephrectomy * female and male patients over 18 years of age exclusion criteria: * bilateral kidney tumor * kidney metastases of a tumor of other origin * renal failure that requires dialysis * pregnant patient * incomplete medical records * patients with diabetes mellitus * patients who cannot tolerate iv fluids * hypersensitivity to the active substance (sinistrin) or to any of the excipients
treatment of rp and lca by primary rpe transplantation

Conditions: Leber Congenital Amaurosis, Retinitis Pigmentosa

Summary: early phase i study of the safety and preliminary efficacy of human primary retinal pigment epithelial (hurpe) cells subretinal transplantation in retinitis pigmentosa (rp) and leber congenital amaurosis (lca) patients


Eligibility criteria:
inclusion criteria: 1. diagnosis of rp or lca; 2. experimental eye with best-corrected visual acuity (bcva) of no more than 35 letters or visual field of less than 10 degree; 3. patient understand and sign the consent form. exclusion criteria: 1. blood routine examination is abnormal (hemoglobin\<10gm/dl; blood platelet count\<100k/mm³; neutrophil count\<1000/mm³) 2. blood biochemistry is abnormal (alt／ast\>1.5; creatinine\>1.3mg/dl) 3. experimental eye has optic nerve atrophy caused by glaucoma 4. experimental eye has retinal detachment, or has received retinal detachment surgery. 5. patients with uveitis and other endophthalmitis 6. patients with other ocular disease affecting vision. 7. patients have participated in clinical study of ocular or systemic drug use in recent 6 months. 8. patients with medical history of malignant cancer (except resected basal cell carcinoma and squamous-cell carcinoma). 9. patients with medical history of myocardial infarction 10. patient with diabetes 11. patient with parkinson disease or alzheimer's disease 12. patients are under the treatment of immunosuppressive agent (except intermittent, low-dose corticosteroid treatment). 13. patients with other medical conditions that restricts the compliance and safety of patients, or affects experimental results.
effect of genetic polymorphism on the occurrence of post-operative atrial fibrillation after cabg

Conditions: Coronary Bypass Graft Surgery; Atrial Fibrillation

Summary: postoperative atrial fibrillation (poaf) is one of the most common complications following coronary artery bypass grafting (cabg) occurring to 20% - 40% of patients. it is associated with prolonged hospitalization, increased hospital costs, increased complications and mortality rate. despite the use of beta blockers, approximately 20% of patients develop atrial fibrillation following cabg surgery, suggesting a role for polymorphism in the genes the aim of the present study is to determine the minor allele frequency of some of the genes that affect the beta blockers' response and to determine the association between polymorphism in these genes and the occurrence of postoperative atrial fibrillation after coronary artery bypass grafting in egyptian patients receiving perioperative beta blockers.


Eligibility criteria:
inclusion criteria: 1. age above 18 years. 2. candidates for cabg surgery without a concurrent valve surgery. 3. patients receiving perioperative beta blockers before new onset of postoperative af. exclusion criteria: 1. patients who have either persistent or permanent af, atrial flutter or atrial tachycardia on ecg obtained on the day of the operation. 2. serum creatinine \>2 mg/dl before the surgery. 3. uncontrolled thyroid disease. 4. recent treatment with amiodarone before the occurrence of poaf
an asthma collaboration to reduce childhood asthma disparities on the navajo nation

Conditions: Asthma in Children

Summary: national jewish health and the university of arizona worked with navajo nation organizations to develop this program to improve the health of children with asthma. the navajo community asthma program will have two main parts. one will train doctors and health care professionals to improve the diagnosis and treatment of asthma. the second part will work with area schools to provide education to school nurses, teachers, and children to help them better understand asthma. the project also works with families to help them know how to best take care of their child's asthma. a major project aim is to make sure that doctors, teachers, and families work together to manage asthma.


Eligibility criteria:
the project will involve three navajo nation agencies: tuba city, chinle, and fort defiance. project interventions will run for one year in each agency. interventions are population-level interventions. no intervention will be administered at the individual level. inclusion criteria: - the study will be conducted within three agencies on the navajo nation, each of which has its own ihs service unit. the three agencies are chinle, tuba city, and fort defiance. exclusion criteria: - this protocol pertains only to the three agencies listed above. community interviewees will be interested candidates who meet the following eligibility criteria: inclusion criteria: 1. able and willing to provide informed consent 2. greater than or equal to 18 years of age 3. guardianship of a child younger than 18 years of age who has been diagnosed with asthma 4. able to read and/or understand english or navajo exclusion criteria: 1. unable or unwilling to provide informed consent 2. younger than 18 years of age, without presence of guardian 3. unable to read and/or understand english or navajo
candis-ii: evaluation of the cognitive-behavioral treatment programme candis

Conditions: Cannabis Use Disorders

Summary: the purpose of this study is to evaluate the effectiveness of the cognitive-behavioral treatment program candis among n=450 patients with cannabis use disorders in a mulicenter randomized-controlled clinical trial (n=11 outpatient treatment centers).


Eligibility criteria:
inclusion criteria: * motivation to change cannabis use * age 16 or older * current (12 mth) regular cannabis use (at least 2 days a week) * informed consent to the study procedures and assessments exclusion criteria: * current alcohol or any illicit drug dependence syndrome according to dsm-iv other than due to cannabis * lifetime history of any psychotic disorder * current severe episode of major depression * current panic-agoraphobic disorder (severe) * severe learning disability, brain damage or pervasive developmental disorder * currently acute suicidality * not fluent in german language * any other current treatment for cannabis use disorders

Keywords: cannabis dependence marijuana cbt efficacy of cbt for cannabis use disorders